MANUFACTURE AND DISTRIBUTION AGREEMENTManufacture and Distribution Agreement • November 4th, 2005 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
Contract Type FiledNovember 4th, 2005 Company Industry JurisdictionThis Manufacture and Distribution Agreement (“Agreement”) made effective as of 12 October, 2005 (“Effective Date”) is made between Gilead Sciences, Inc., a Delaware corporation (“Gilead”), with its principal place of business at 333 Lakeside Drive, Foster City, CA 94404, and Aspen Pharmacare Holdings Limited, a South African company (“Aspen”), with its principal place of business at Building 8, Healthcare Park, Woodlands Drive, Woodmead, Sandton 2052, Gauteng, Republic of South Africa. Gilead and Aspen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
GILEAD WORLD MARKETS, LTD.-PHARMACHEM TECHNOLOGIES (GRAND BAHAMA), LTD. TENOFOVIR DISOPROXIL FUMARATE MANUFACTURING SUPPLY AGREEMENTSupply Agreement • November 4th, 2005 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
Contract Type FiledNovember 4th, 2005 Company IndustryTHIS SUPPLY AGREEMENT (“Agreement”) is entered into as of July 17, 2003, by and between PharmaChem Technologies (Grand Bahama), Ltd., a Commonwealth of the Bahamas company (“PharmaChem”) having its principal place of business at [ * ] Freeport, Grand Bahama, Commonwealth of The Bahamas, , and Gilead World Markets, Ltd., a company operating under the laws of the Cayman Islands (“GWM”) having its principal place of business at Queensgate House, South Church Street, PO Box 1234GT, Grand Cayman. PharmaChem and GWM may be referred to individually as a “Party” and collectively as the “Parties” in this Agreement.
ROYALTY SALE AGREEMENTLicense Agreement • November 4th, 2005 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • Georgia
Contract Type FiledNovember 4th, 2005 Company Industry JurisdictionThis Royalty Sale Agreement (this “Agreement”) is made and entered into as of July 18, 2005 by and among Gilead Sciences, Inc., a Delaware corporation (“Gilead”), Emory University, a not-for-profit corporation organized under the laws of the State of Georgia (“Emory”), and Investors Trust & Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, a unit trust organized under the laws of the Republic of Ireland (“Royalty Pharma”) (Gilead, Emory and Royalty Pharma are each a “Party” and collectively the ”Parties”).